TB-402 is a human antibody binding to Factor VIII, which plays a crucial role in the coagulation of the blood. It is expected to be developed as a potential treatment to prevent blood clot formation in connection with certain types of heart arrhythmia, such as atrial fibrillation.
Investigated for use/treatment in atrial fibrillation and thrombosis.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.